All Fulcrum Publications

December 6, 2025

Pociredir, a Novel Oral Once-Daily Fetal Hemoglobin Inducer: Results from the Phase 1b PIONEER Study in Adult Participants with Severe Sickle Cell Disease and Hydroxyurea Intolerance or Unresponsiveness

Sheinei Alan, Johnny Mahlangu, Michael Birrer, Marshall Stagg II, Debra A. Ferman, Rita Lemming, Caterina Minniti, Thomas Winkler, Adeyemi Adenola, Modupe Idowu

October 18, 2025

FTX-6274, an EED Inhibitor, Demonstrates Robust Efficacy in Castration Resistant Prostate Cancer (CRPC)

Suchi Raghunathan, Billy Stuart, Keqiang Xie, Serena Silver, Ivan Efremov, Jeff Jacobs, Brian Lucas

October 2, 2025

Real-World Data Demonstrating the Correlation Between Increased Fetal Hemoglobin and Reduced VOC Rates in SCD

Sheinei Alan, Caterina Minniti, William Denney

June 14, 2025

Pociredir, a Potent and Selective EED Inhibitor for the Treatment of Sickle Cell Disease, Induces Target Engagement and Gene Expression Changes that are Specific and Reversible in Wild-Type Mice

Allysa Allen, Caterina Minniti, David Matson, Caroline Sartain, Suchi Raghunathan, Emily Fitz, Briana Steward, Daniel Osorio, Alexander Koch, Billy Stuart, Jeffrey Jacobs

June 13, 2025

Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of the Novel Oral Fetal Hemoglobin (HbF) Inducer Pociredir in Healthy Adults in a Phase 1 Study

Caterina Minniti, Adeyemi Adenola, Thomas Winkler, John Jiang, Utpal Gupta, Iain Fraser

March 19, 2025

Topline Efficacy and Safety Results From REACH: Phase 3 Placebo-Controlled Trial of Losmapimodfor Facioscapulohumeral Muscular Dystrophy (FSHD)

June 24, 2024

Losmapimod, a p38α/βMAPK inhibitor for the Potential Treatment of Patients with FSHD

Jeff Jacobs, PhD

June 15, 2024

An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1

Joost Kools, Nicol Voermans, John G. Jiang, Olga Mitelman, Michelle L. Mellion, Vivekananda Ramana, Baziel G.M. van Engelen

June 14, 2024